The growing findings, showing differential IGF-II targets with cancer-promoting function activated through the IR-A but not via insulin on the same receptor [15,29], nor by the IGF1R [30], further support such view and point at the IR-A expression as a possible functional discriminant between diabetes and cancer and a valid biomarker for cancer along with other established biomarkers. The gene discussed is IGF2; the disease is cancer.